Pleco Therapeutics develops Plecoid™ therapies that enhance the efficacy of existing chemotherapy by modulating protein expression in the cancer microenvironment and eliminating toxic metal burdens within cells. This approach aims to extend patient lifespans and improve their quality of life through more effective cancer treatment options.
Funding
$33.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments are limited by the cancer microenvironment and the presence of toxic metals within cancer cells, which can reduce the effectiveness of chemotherapy. This can lead to shorter lifespans and reduced quality of life for patients.
Solution
Pleco Therapeutics develops Plecoid™ therapies designed to enhance the efficacy of existing chemotherapy treatments. Their approach focuses on modulating protein expression within the cancer microenvironment and eliminating toxic metal burdens inside cancer cells. By addressing these factors, Pleco Therapeutics aims to improve the effectiveness of chemotherapy, potentially extending patient lifespans and enhancing their quality of life.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy and oncologists seeking to improve treatment outcomes.
Features
- Plecoid™ therapies target the cancer microenvironment to improve treatment response.
- Modulation of protein expression to create a more favorable environment for chemotherapy.
- Removal of toxic metal burdens within cancer cells to reduce resistance to treatment.